Comments BridgeBio Pharma (BBIO) on Wednesday said it plans to offer $550 million of convertible senior notes due 2033 in a private placement to qualified institutional buyers. The company said it expects to grant initial purchasers an option to buy up Post navigation Multi-Omics Reveal Personalized Prognosis in Thyroid CancerDigital SHERLOCK: Rapid Detection and Resistance Profiling of Candida auris
